Technical Analysis for SHPG - Shire plc

Grade Last Price % Change Price Change
grade F 145.25 -1.74% -2.57
SHPG closed down 1.74 percent on Friday, October 20, 2017, on approximately normal volume. Note that the stock is in oversold territory based on its Slow Stochastic indicator (14, 3, 3) -- sideways movement or a bounce should not be unexpected.

Earnings due: Oct 27

Track This Stock
Watchlist Portfolio
Trend Table & Recent Alerts
ADX Long-Term Intermediate-Term Short-Term
Weak or Absent Down Down Down
See historical SHPG trend table...

Date Alert Name Type % Chg
Oct 20 Lower Bollinger Band Walk Other 0.00%
Oct 19 Stochastic Reached Oversold Other -1.74%
Oct 19 Bollinger Band Squeeze Range Contraction -1.74%
Oct 19 Lower Bollinger Band Walk Other -1.74%
Oct 19 Calm After Storm Range Contraction -1.74%

Older signals for SHPG ...

Get this analysis on your stocks daily!

Let us help you stay on top of your investments. We will alert you to important technical developments on your portfolio.
Basic chart:

Shire plc, a specialty biopharmaceutical company, engages in the research and development, manufacture, sale, and distribution of pharmaceutical products. It operates in three segments: Specialty Pharmaceuticals (SP), Human Genetic Therapies (HGT), and Regenerative Medicine (RM). The SP segment offers products for the treatment of attention deficit and hyperactivity disorder (ADHD), including VYVANSE/VENVANSE, a pro-drug stimulant; INTUNIV, an alpha-2A receptor agonist; EQUASYM, a methylphenidate hydrochloride; and ADDERALL XR, an extended release treatment for ADHD. It also produces PENTASA and LIALDA/MEZAVANT for the treatment of ulcerative colitis; and RESOLOR, a 5-HT4 receptor agonist for oral symptomatic treatment of chronic constipation in women. In addition, this segment provides FOSRENOL, a phosphate binder for use in end-stage renal failure patients receiving dialysis; and XAGRID for the reduction of elevated platelet counts in at-risk essential thrombocythemia patients, as well as for the treatment of thrombocythemia. The HGT segment offers REPLAGAL for the treatment of Fabry disease; ELAPRASE for the treatment of hunter syndrome; VPRIV for the treatment of type 1 Gaucher disease; and FIRAZYR for the symptomatic treatment of acute attacks of hereditary angioedema. The RM segment provides DERMAGRAFT, a bio-engineered skin substitute that assists in restoring damaged tissue. The company also licenses its patented antiviral products for human immunodeficiency virus and hepatitis B virus. In addition, it is developing various products in the areas of behavioral health, gastrointestinal, HGT, RM, and other therapeutic areas. The company markets its products directly to government hospitals, clinics, pharmacies, and other agencies; and through wholesalers and distributors. It has operations in North America, the United Kingdom, the Republic of Ireland, and internationally. Shire plc was founded in 1986 and is headquartered in Dublin, Ireland.
Is SHPG a Buy, Sell or Hold?
Indicator Bull Case Neutral / Hold Bear Case
50 DMA
200 DMA
ADX Trend
Oversold / Overbought
Relative Strength
Summary: Counts: 0 bullish, 3 bearish and 2 neutral indicators. You may wish to incorporate that into your trading strategies.
Indicator Value
52 Week High 192.64
52 Week Low 139.36
Average Volume 1,105,583
200-Day Moving Average 167.2604
50-Day Moving Average 151.5256
20-Day Moving Average 151.815
10-Day Moving Average 150.678
Average True Range 2.9272
ADX 12.83
+DI 20.56
-DI 33.68
Chandelier Exit (Long, 3 ATRs ) 149.0684
Chandelier Exit (Short, 3 ATRs ) 153.8116
Upper Bollinger Band 157.3716
Lower Bollinger Band 146.2584
Percent B (%b) -0.09
BandWidth 7.320225
MACD Line -1.5334
MACD Signal Line -0.8115
MACD Histogram -0.7219
Pivot Point Level Traditional / Classic Fibonacci Demark Woodie Camarilla
Resistance 4 (R4) 148.15
Resistance 3 (R3) 148.39 147.68 147.66
Resistance 2 (R2) 147.68 146.94 147.55 147.50
Resistance 1 (R1) 146.46 146.48 146.11 146.22 147.34
Pivot Point 145.75 145.75 145.57 145.62 145.75
Support 1 (S1) 144.53 145.01 144.18 144.29 143.16
Support 2 (S2) 143.82 144.55 143.69 143.00
Support 3 (S3) 142.60 143.82 142.84
Support 4 (S4) 142.36